A single‐arm Phase II study (WJOG790L) has evaluated the efficacy of Osimertinib in treating T790M‐negative NSCLC patients with resistance to first/second‐generation EGFR‐TKIs [9]. Here, EGFR is linked to non-small cell lung carcinoma.